Mainz Biomed N.V. (MYNZ)
NASDAQ: MYNZ · Real-Time Price · USD
2.210
-0.230 (-9.43%)
At close: May 19, 2025, 4:00 PM
2.310
+0.100 (4.52%)
After-hours: May 19, 2025, 7:51 PM EDT
Company Description
Mainz Biomed N.V. develops and sells in-vitro diagnostic (IVD) tests for the early detection of cancer in the United States and Europe.
It offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. The company also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer.
In addition, it operates a clinical diagnostic laboratory; and distributes its IVD kits to third-party laboratories.
The company has a collaboration agreement with Thermo Fisher Scientific Inc. for the development and commercialization of colorectal cancer screening product.
Mainz Biomed N.V. was founded in 2008 and is based in Mainz, Germany.
Mainz Biomed N.V.
| Country | Germany |
| Founded | 2021 |
| IPO Date | Nov 5, 2021 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 26 |
| CEO | Guido Baechler |
Contact Details
Address: Robert Koch Strasse 50 Mainz, 55129 Germany | |
| Phone | 49 6131 554 2860 |
| Website | mainzbiomed.com |
Stock Details
| Ticker Symbol | MYNZ |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $5.00 |
| CIK Code | 0001874252 |
| CUSIP Number | N5436L101 |
| ISIN Number | NL0015000LC2 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Guido Baechler | Chief Executive Officer and Executive Director |
| Dr. Frank Krieg-Schneider | Chief Technology Officer |
| Philipp Freese | Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 16, 2025 | EFFECT | Notice of Effectiveness |
| May 15, 2025 | SCHEDULE 13G/A | Filing |
| May 14, 2025 | F-1/A | [Amend] Registration statement for certain foreign private issuers |
| May 14, 2025 | F-1 | Registration statement for certain foreign private issuers |
| May 2, 2025 | 6-K | Report of foreign issuer |
| Apr 9, 2025 | DRS | [Cover] Draft Registration Statement |
| Apr 1, 2025 | 6-K | Report of foreign issuer |
| Mar 31, 2025 | 20-F | Annual and transition report of foreign private issuers |
| Mar 13, 2025 | 6-K | Report of foreign issuer |
| Feb 14, 2025 | SCHEDULE 13G | Filing |